



July 27, 2011

Dear Steele Family & Friends:

As I stated last year, I would once again like to thank you and the Christopher Steele Foundation for your donations benefiting sarcoma research here at Northwestern. I am truly grateful for your continued fundraising efforts as we celebrate the 6<sup>th</sup> Annual Christopher Steele Foundation Memorial Golf Outing. Your dedication and success with this annual fundraising activity is inspiring. I would like to take this opportunity to bring you up to speed with the recent developments of my research.

The Robert H. Lurie Comprehensive Cancer Center of Northwestern University continues to treat a large volume of sarcoma patients. We continue to build upon our participation in clinical trials and aim to offer effective and novel therapies to our patients. As of July 2011, our sarcoma program at Northwestern has completed accrual on five clinical trials; both phase II and phase III, and have five clinical trials currently accruing patient and 3 due to be open to enrollment in the next one to three months.

Collaborations are currently underway to form a key Sarcoma group in the Midwest with the specific aim at creating clinical trials that can answer the question of how best to treat our patients, how best to prolong survival while maintaining quality of life and which classes of drugs are most effective in different subtypes of sarcomas. This group of 4 dedicated and devoted Sarcoma Programs will meet in November 2011 to discuss how best to move forward.

The fundraising efforts are crucial to maintaining our robust program at Northwestern and every penny raised is used to support the mission set forward by the Christopher Steele Foundation.

Again, on behalf of my staff and those who will benefit from your generous donation, I thank you.

Sincerely,

A handwritten signature in black ink that reads "M. Agulnik".

Mark Agulnik, MD  
Assistant Professor

cc: David Sack, Director, Northwestern Memorial Foundation